Global Economy

Trump experienced oxygen drops Friday and Saturday but has improved and could be discharged Monday, doctor says

White House physician Sean Conley answers questions surrounded by other doctors, during an update on the condition of US President Donald Trump, on October 4, 2020, at Walter Reed Medical Center in Bethesda, Maryland.
Brendan Smialowski | AFP | Getty Images

President Donald Trump experienced two drops in his oxygen levels over the course of his coronavirus illness but has improved and may be discharged as soon as Monday, Trump’s physician, Dr. Sean Conley, said on Sunday. 

“The president has continued to improve,” Conley told reporters outside the Walter Reed National Military Medical Center, where Trump is being treated. “As with any illness, there are frequent ups and downs over the course.”

Conley said Trump was doing well Thursday night into Friday morning and was only experiencing mild symptoms with his blood oxygen levels in the high 90s. 

Conley said that by late Friday morning the president was running a high fever and his oxygen saturation levels had dipped below 94%. Healthy adults generally have blood oxygen levels of 95% or higher. 

“Given these developments, I was concerned for possible rapid progression of the illness,” Conley said. 

Trump was then given supplemental oxygen and “after about a minute” his levels were back above 95%. The president was on supplemental oxygen for about an hour Friday, Conley said. 

On Saturday, Trump’s oxygen saturation dipped to about 93%, the doctor said. It’s unclear if he was given oxygen on Saturday. The doctors monitored Trump and his oxygen levels went back up. The president’s blood oxygen level is currently at 98%, Conley said.

Conley also said that the president has been administered dexamethasone, a steroid that treats inflammation in Covid-19 patients and has been shown to help patients with severe or critical illness. However, it is generally not used in mild or moderate Covid-19 cases. Trump also completed a second dose of remdesivir on Saturday. 

Still, doctors said Trump could be discharged as early as Monday to continue his treatment at the White House. The president has entered his third day in the hospital on Sunday after contracting the virus last week.

Dr. Sean Dooley, a pulmonologist at Walter Reed, said the president has been without a fever since Friday morning with favorable vital signs and no shortness of breath or any other significant respiratory symptoms.

The Sunday briefing comes a day after a presentation from the doctors that sowed confusion and concern over the president’s condition and raised new questions about when it was known that Trump was ill.  

Trump’s team of doctors acknowledged on Sunday that they gave an overly positive description of the president’s condition on Saturday. 

“I didn’t want to give any information that might steer the course of illness in another direction, and in doing so, you know, it came off that we were trying to hide something, which wasn’t necessarily true,” Conley said.

Dr. Scott Gottlieb, former FDA chief in the Trump administration, told CNBC’s Shepherd Smith that he’s more concerned now about the president’s condition than he was before the Sunday briefing, citing the president’s dexamethasone treatment. 

“They threw the kitchen sink at POTUS. The care will help. But they saw signs he was decompensating,” Gottlieb said of the president. “The dexamethasone was a key disclosure. A lot of us were speculating that but to know that now is a key fact.”

Trump’s coronavirus diagnosis was announced just before 1 a.m. EST on Friday. It’s unclear when the president was infected with the virus.

The president released a video on Saturday evening saying he was starting to feel good and would be back soon, though he acknowledged the next few days will be the “real test” during ongoing treatment. 

White House physician Sean Conley answers questions surrounded by other doctors, during an update on the condition of US President Donald Trump, on October 4, 2020, at Walter Reed Medical Center in Bethesda, Maryland.
Brendan Smialowski | AFP | Getty Images

Disclosure: Scott Gottlieb is a CNBC contributor and is a member of the boards of Pfizer, genetic testing start-up Tempus and biotech company Illumina. Pfizer has a manufacturing agreement with Gilead for remdesivir. Gottlieb also serves as co-chair of Norwegian Cruise Line Holdings′ and Royal Caribbean‘s “Healthy Sail Panel.”

Let’s block ads! (Why?)

Top News and Analysis (pro)

Leave a Reply

Your email address will not be published. Required fields are marked *